Spinal muscular atrophy (SMA) is an inherited disease of anterior horn cells. It varies in severity from type 1A (SMA1; or type 0), for which continuous noninvasive ventilatory support (CNVS) and enteral nutrition are required before 6 months of age (10% of cases); to typical, for which CNVS and enteral nutrition are needed by 18 months (75%) of age; to mild, when CNVS and enteral nutrition are subsequently needed (15%).
Spinal muscular atrophy (SMA) is an inherited disease of anterior horn cells. It varies in severity from type 1A (SMA1; or type 0), for which continuous noninvasive ventilatory support (CNVS) and enteral nutrition are required before 6 months of age (10% of cases); to typical, for which CNVS and enteral nutrition are needed by 18 months (75%) of age; to mild, when CNVS and enteral nutrition are subsequently needed (15%). 1, 2 Without respiratory support, SMA1 has 50% mortality by 7 months of age and 90% by 1 year of age. 3 
Importance of Prolonging Life
Parents and providers have several options available: they can let the infant die of respiratory failure; they can acquiesce to a tracheotomy, which is usually unnecessary; or they can use noninvasive ventilatory support (NVS) and mechanical insufflation-exsufflation (MIE).
Although there had been little hope for effective treatments, this outcome is no longer the case. The first improvements in strength using allogenic mesenchymal stem cells have been reported, 4 Benefits of NVS Over Tracheotomy Sleep NVS, but not polysomnographic titrations of low span "BiPAP," reverses paradoxing and can result in the lungs of children with SMA1 who have 0 mL of vital capacity being able to receive > 2 L of air by adolescence (Figs 2, 3) . 7 In addition to preventing chest deformities (Fig 1) , sleep NVS helps maintain pulmonary compliance and promotes growth. 14 MIE via oronasal interfaces may facilitate this once cooperation with it becomes possible.
Although survival past 20 years of age is possible for these children with tracheostomies as well as by CNVS and MIE as needed, immediately following tracheotomy, children with typical SMA1 usually become and remain continuously dependent on tracheostomy ventilation, never develop speech, and may eventually die of tuberelated complications. 4 Of the 9 part-time NVS users in our care who underwent tracheotomy (eight when pressured by local out-of-state physicians, and one due to inadequate presence of adept home care providers), four of the eight died within 2 years of tracheotomy. Patients extubated to CNVS and NVS invariably wean back to their prehospitalization regimens; 80% produce some speech; and 20% speak with fair articulation past 10 years of age and occasionally after age 20 years. 5 Also, NVS requires less home care resources than ventilation via tracheostomy, thus lowering costs of care. 12 
Long-term Outcomes
Of 66 children in two centers who began sleep nasal NVS at 4 months of age (range, 1-10 months) and used it < 24 h per day for 3.6 AE 6.3 years, 37 became CNVS dependent (almost one-half of whom before 10 years journal.publications.chestnet.org of age). For 14 children, this scenario occurred without any hospitalizations. Twenty-one of the 37 have continued CNVS for a mean 11.6 AE 3.3 years; nine children are now > 20 years of age despite having had no ability to breathe on their own for > 10 years 15 ; two died after 3 years of age in out-of-state hospitals that do not offer CNVS or MIE; and two of the 44 local children also died at home before 3 years of age. Because four have only residual eye movements, they drool but do not aspirate sufficiently to decrease oxygen saturation; remarkably, their MIE (cough) flows are > 350 L/m. Already using CNVS for 20 years, these patients are likely to live many more years and never need tubes for ventilatory support (Figs 3-5 ). Had they undergone tracheotomy as infants, they may not have survived because, for similar conditions such as amyotrophic lateral sclerosis, the majority die of tube-related complications. 11 Many clinicians argue that survival is not greatly improved by "noninvasive ventilation", which for them means CPAP or low span bi-level PAP rather than NVS, but also that quality of life (QOL) is too poor to justify tracheotomy. Of the 187 members of pediatric medical societies unaware of extubation to CNVS and MIE, 48% recommended against intubation. 16 Eighty percent of 33 Japanese pediatricians also recommended against interventions to prolong life. 17 Medical directors of neuromuscular disease clinics have withheld information on ventilation because "parents are too biased to make appropriate decisions." 18 Although 70
health-care professionals judged the QOL of these patients to be < 2 on a Likert scale of 0 to 10 and most advised against ventilator use, 104 care providers (mostly parents) made the following Likert scale estimates for 66 such children (on a scale of 0-10): QOL, 7.8; provider's QOL, 8.0; child's happiness, 8.5; and worthwhile nature of the child's life, 9.6. On a scale of 0 to 7, they estimated the children's life satisfaction to be 6.0. Although the providers considered the effort in raising these children to be 60% greater than for their other children, they did not consider this responsibility to be an unreasonable burden. 19 With long experience with both tracheostomy and CNVS for SMA1 and milder conditions, I feel that it is inappropriate to criticize CNVS without trying it or to assess QOL from an able-bodied clinician's perspective rather than from a patient's perspective. to gauge disabled patients' life satisfaction and potential for social and vocational productivity and refrain from letting their QOL judgments affect patient management decisions.
Conclusions
Children with SMA1 can be managed indefinitely by using CNVS and MIE. Few with SMA1 or milder neuromuscular disorders should require tracheostomies for long-term survival.
